Company intelligenceMRK
Merck
NYSE · Pharmaceutical Preparations
Q2 FY2026Quarter ended Jun 30, 2026 (13-week quarter)Data as of Oct 13, 2026
This quarter's figures come from the company's SEC filing.
Blockhaven company read
Revenue grew 5.1% year over year, little changed from 4.9% in the prior quarter.
GAAP net income swung to a loss of $1.33 billion from $4.43 billion a year earlier (−$0.54 per diluted share versus $1.76).
Business trendDeterioratingGAAP net income weakened; revenue growth was roughly steady.
Latest reported quarter
13-week quarter · Reported Aug 4, 2026
RevenueGAAP
- Latest
- $16.6 billion
- Year ago
- $15.8 billion
- Change
- +5.1% (Up year over year)
Net incomeGAAP
- Latest
- −$1.33 billion
- Year ago
- $4.43 billion
- Change
- −130.2% (Down year over year)
Diluted EPSGAAP
- Latest
- −$0.54
- Year ago
- $1.76
- Change
- −130.7% (Down year over year)
Diluted sharesGAAP
- Latest
- 2.47 billion
- Year ago
- 2.51 billion
- Change
- −1.7% (Down year over year)
Operating cash flowGAAP
- Latest
- $5.37 billion
- Year ago
- $3.29 billion
- Change
- +63.1% (Up year over year)
Derived from year-to-date filings
Capital expendituresGAAP
- Latest
- $893 million
- Year ago
- $764 million
- Change
- +16.9% (Up year over year)
Derived from year-to-date filings
Cash and equivalentsGAAP
- Latest
- $6.85 billion
- Year ago
- $8.01 billion
- Change
- −14.5% (Down year over year)
| Measure | Basis | Latest quarter | Year ago | Change |
|---|---|---|---|---|
| Revenue | GAAP | $16.6 billion | $15.8 billion | +5.1% (Up year over year) |
| Net income | GAAP | −$1.33 billion | $4.43 billion | −130.2% (Down year over year) |
| Diluted EPS | GAAP | −$0.54 | $1.76 | −130.7% (Down year over year) |
| Diluted shares | GAAP | 2.47 billion | 2.51 billion | −1.7% (Down year over year) |
| Operating cash flowDerived from year-to-date filings | GAAP | $5.37 billion | $3.29 billion | +63.1% (Up year over year) |
| Capital expendituresDerived from year-to-date filings | GAAP | $893 million | $764 million | +16.9% (Up year over year) |
| Cash and equivalents | GAAP | $6.85 billion | $8.01 billion | −14.5% (Down year over year) |
This quarter's figures come from the company's SEC filing. GAAP unless labelled. Non-GAAP and company-defined measures are labelled.
Growth and margins
Revenue growth
+5.1%
Roughly stable versus +4.9% in the prior quarter (year over year, GAAP).
Margins (GAAP)
- Net margin −8.0%Compressed −3605 bp vs 28.0% a year ago
Guidance
StatusNone found in the latest release
Recent events
- ManagementAn executive or director change (8-K Item 5.02)
Sources and dates
Filings and dates
- 8-K earnings releasefiled Aug 4, 2026
- SEC filings (10-Q, 10-K financial data)
- Data as of Oct 13, 2026. Quarter ended Jun 30, 2026.
Data health
Some figures could not be cross-checked and are omitted.
- SEC company recordAvailable
- SEC financial dataAvailable
- SEC filing documentsAvailable
- Earnings releasePartial
Descriptive company facts from SEC filings and the issuer's own earnings release. GAAP figures are labelled as such. Not investment advice, a rating or a recommendation. Disclosures